You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫藥業(002422.SZ):子公司核心產品蘆康沙妥珠單抗(sac-TMT)於2024年歐洲腫瘤內科學會大會上公佈研究結果
格隆匯 09-09 08:35

格隆匯9月9日丨科倫藥業(002422.SZ)公佈,公司近日獲悉,在 2024 年 9 月 13 日至 17 日於西班牙巴塞羅納舉行的 2024 年歐洲腫瘤內科學會(ESMO)大會上,公司控股子公司四川科倫博泰生物醫藥股份有限公司(以下簡稱"科倫博泰")將公佈以下研究結果:1.在當地時間 2024 年 9 月 15 日 14:55 至 15:00 的小型口頭報吿環節(報吿編號:716MO),公佈抗TROP2 ADC蘆康沙妥珠單抗(sac-TMT,前稱SKB264/MK2870)聯合帕博利珠單抗(可瑞達?)用於復發或轉移性宮頸癌(CC)患者的療效及安全性的研究結果;

2.在當地時間 2024 年 9 月 15 日 14:50 至 14:55 的小型口頭報吿環節(報吿編號:715MO)公佈蘆康沙妥珠單抗(sac-TMT)單藥療法用於既往接受過治療的晚期子宮內膜癌(EC)及卵巢癌(OC)患者的 2 期研究的安全性及療效的研究結果;

3.在當地時間 2024 年 9 月 16 日,以壁報形式(報吿編號:386P)公佈蘆康沙妥珠單抗(sac-TMT)對比化療用於既往接受過治療的晚期三陰性乳腺癌(TNBC)患者的 3 期研究(OptiTROP-Breast01)中,對既往接受過或未接受過 PD-(L)1 抑制劑治療的患者的探索性分析研究結果。

上述研究的摘要已於當地時間 2024 年 9 月 9 日發佈於 ESMO 大會的官方網站。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account